Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

[18F]FDG (2R,5R)-3-fluoro-6- (hydroxymethyl)oxane-2...

Synonyms:

Pietrini, P. et al., Srinivasan, G. et al., Chen, D.L. et al., Schmidt, K. et al., Mamede, M. et al., et al.

Kornblum, Araujo, Annala, Tatsukawa, Phelps, Cherry, Pietrini, Dani, Furey, Alexander, Freo, Grady, Mentis, Mangot, Simon, Horwitz, Haxby, Schapiro, Ibach, Poljansky, Marienhagen, Sommer, Männer, Hajak, Miller, Miller, Mehrotra, Agarwal, Mock, Zheng, Badve, Hutchins, Sledge,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of [18F]FDG

Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases [1].
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer [2].
[18F]Fluorodeoxyglucose scans were performed on 9 patients with Parkinson's disease and 14 normal subjects [3].
Thus PET using [18F]fluorodeoxyglucose can contribute to the optimum management of patients with primary brain tumors [4].
In patients with malignant gliomas, [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) may discriminate tumor progression from radionecrosis [5].

Psychiatry related information on [18F]FDG

We evaluated 12 long-term survivors of childhood leukemia using [18F]fluorodeoxyglucose positron emission tomography, computed tomography scans, clinical neurological examinations, and neuropsychological tests [6].
[18F]FDG positron emission tomography (PET) scans of 14 patients comprising the clinical prototypes of dementias that are considered to be associated with frontotemporal lobar degeneration (FTLD) were compared to a population of 15 patients with early onset Alzheimer's disease (EOAD) [7].
Seven patients, presenting CSWS associated with neuropsychological deterioration (isolated aphasia, three cases; language disturbances with more widespread cognitive deterioration, three cases; isolated apraxia, one case) were studied using PET with [18F]fluorodeoxyglucose (FDG) [8].
METHOD: Positron emission tomography (PET) with [18F]fluorodeoxyglucose was used to determine cerebral metabolic activity in six female patients with a DSM-III-R diagnosis of panic disorder and in six healthy female volunteers [9].
To test this hypothesis, we measured regional cerebral metabolism with 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) and positron emission tomography (PET) in 11 patients with "pure" amnesia [10].

High impact information on [18F]FDG

[18F]Fluorodeoxyglucose PET is also useful in some endocrine tumors, particularly in recurrent or metastatic thyroid cancer where the degree of accumulation of the radionuclide has prognostic value [11].
Muscle glucose uptake of the thighs was measured simultaneously by dynamic [18F]fluorodeoxyglucose positron-emission tomography scan [12].
We now demonstrate that microPET, a PET scanner developed for use with small animals, can be used to assess metabolic activity in different regions of the conscious rodent brain using [18F]fluorodeoxyglucose (FDG) as the tracer, and to monitor changes in neuronal activity [13].
[18F]fluorodeoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability [14]?
BACKGROUND: New high-energy collimators for single photon emission computed tomography (SPECT) cameras have made imaging of positron-emitting tracers, such as [18F]fluorodeoxyglucose (18FDG), possible [14].

Chemical compound and disease context of [18F]FDG

Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method [3].
PURPOSE: Whole-body 18F-fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) imaging before and after induction therapy was prospectively evaluated in patients with esophageal cancer to determine whether changes in PET images could measure response to therapy [15].
Positron emission tomographic imaging with [18F]fluorodeoxyglucose ([18FDG]) could be used as a noninvasive alternative to quantify lung inflammation [16].
METHODS: To assess the potential of thymidine for imaging brain tumors, 20 patients with untreated (n = 14) and recurrent (n = 6) supratentorial intracranial tumors were studied with PET by using 2-[11C]thymidine (Tdr), and the results were compared with [18F]fluorodeoxyglucose (FDG) PET data [17].
We used [18F]FDG and PET in patients with obsessive-compulsive disorder (OCD) to evaluate cerebral metabolic involvement before and after treatment with serotonin-specific reuptake inhibitors [18].

Biological context of [18F]FDG

As studied by [18F]FDG PET under stable normoglycemic hyperinsulinemic conditions, MGU is not reduced in patients with NIDDM and CAD in spite of peripheral insulin resistance [19].
Images in neuroscience. Neuroimaging, I.PET with [18F]fluorodeoxyglucose [20].
METHOD: Regional cerebral glucose metabolism was assessed by means of positron emission tomography (PET) with [18F]fluorodeoxyglucose in eight younger (mean age = 35 years, SD = 2) and eight older (mean age = 50, SD = 7) healthy, nondemented adults with trisomy 21 Down's syndrome [21].
When either of the kinetic models designed for homogeneous tissues was applied to heterogeneous tissues, estimates of the rate constant for efflux of [18F]FDG from the tissue (k2*) and of the rate constant for phosphorylation of [18F]FDG (k3*) decreased as the duration of the experimental period was increased [22].
Positron emission tomography with [11C]carbon monoxide to measure blood volume, [18F]fluoromethane to measure perfusion, and [18F]fluorodeoxyglucose to measure glucose utilization was done at baseline, and after 24 hours, 72 hours, and 4 weeks of treatment [23].

Anatomical context of [18F]FDG

Myocardial viability in patients with chronic coronary artery disease. Comparison of 99mTc-sestamibi with thallium reinjection and [18F]fluorodeoxyglucose [24].
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography [4].
Whole-body [18F]fluorodeoxyglucose positron emission tomography showed abnormal uptake in the mediastinum in these 3 patients in accordance with the expected location of the malignancy [25].
Source propagation of interictal spikes in temporal lobe epilepsy. Correlations between spike dipole modelling and [18F]fluorodeoxyglucose PET data [26].
OBJECTIVE: To determine the relationships among lung [18F]FDG uptake, bronchoalveolar lavage (BAL) neutrophil concentrations, and pulmonary function in patients with CF [16].

Associations of [18F]FDG with other chemical compounds

In the present study, end-diastolic wall thickness at rest and dobutamine-induced systolic wall thickening assessed by magnetic resonance imaging (MRI) were compared with corresponding [18F]fluorodeoxyglucose uptake as assessed by positron emission tomography (FDG-PET) [27].
METHODS AND RESULTS: Dynamic positron emission tomographic imaging with [13N]ammonia and [18F]fluorodeoxyglucose (FDG) to assess myocardial perfusion and glucose uptake was performed in 39 patients with chronic anterior wall dysfunction undergoing coronary revascularization [28].
METHOD: Positron emission tomography with [18F]fluorodeoxyglucose was used to determine cerebral metabolic activity in 17 healthy volunteers while an acute psychotic state was induced simultaneously by the administration of subanesthetic doses of ketamine [29].
METHODS: Sixteen healthy right-handed men underwent scanning with PET and [18F]fluorodeoxyglucose (FDG) twice: before placebo and before lorazepam (30 micrograms/kg) [30].
The SPECT images were directly compared to gadolinium contrast-enhanced MR images as well as to [18F]fluorodeoxyglucose (FDG) PET scans and 201Tl SPECT scans [31].

Gene context of [18F]FDG

[18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung [32].
CONCLUSION: Gluts, especially Glut-1, are responsible for [18F]FDG uptake in a nude mouse model of colon cancer rather than hexokinase activity [33].
PURPOSE: The aim of this study was to evaluate the relationships among [18F]fluorodeoxyglucose ([18F]-FDG) uptake, Glut-1 and HK-II expressions, and grade of inflammation in resected lung lesions [32].
METHOD: Using positron emission tomography and [18F]fluorodeoxyglucose, CMRglc were compared between 10 girls with ADHD (14.10 +/- 1.91 years) and 11 normal girls (14.3 +/- 1.70 years) [34].
We measured the cerebral metabolic rate of glucose (CMRglc) by using positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG) and the choline acetyltransferase (ChAT) activity at 3 days and 3 months after destruction of the nucleus basalis magnocellularis (NBM) [35].

Analytical, diagnostic and therapeutic context of [18F]FDG

Presence or absence of abnormal [18F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis [36].
While the [18F]FDG PET scan cannot currently localize an epileptogenic zone independently, the absence of focal hypometabolism or its presence contralateral to a presumed EEG focus suggests the need for additional electrophysiological data [37].
METHODS: We performed positron emission tomography using [18F]fluorodeoxyglucose and structural magnetic resonance imaging at baseline in 60 cognitively normal community-dwelling older subjects who were part of a longitudinal cohort study [38].
METHOD: Positron emission tomography with [18F]fluorodeoxyglucose and matching MRI scans were obtained in 20 never-medicated patients with schizophrenia and 15 normal volunteers [39].
Local CMRGlc values were determined for 13 regions in each hemisphere from tomographs of patients with Alzheimer's, Huntington's, and Parkinson's diseases who were studied using [18F]fluorodeoxyglucose with positron emission computed tomography [40].

References

Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. Akhurst, T., Kates, T.J., Mazumdar, M., Yeung, H., Riedel, E.R., Burt, B.M., Blumgart, L., Jarnagin, W., Larson, S.M., Fong, Y. J. Clin. Oncol. (2005) [Pubmed]
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. Sasaki, R., Komaki, R., Macapinlac, H., Erasmus, J., Allen, P., Forster, K., Putnam, J.B., Herbst, R.S., Moran, C.A., Podoloff, D.A., Roth, J.A., Cox, J.D. J. Clin. Oncol. (2005) [Pubmed]
Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method. Kuhl, D.E., Metter, E.J., Riege, W.H. Ann. Neurol. (1984) [Pubmed]
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Glantz, M.J., Hoffman, J.M., Coleman, R.E., Friedman, A.H., Hanson, M.W., Burger, P.C., Herndon, J.E., Meisler, W.J., Schold, S.C. Ann. Neurol. (1991) [Pubmed]
Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Janus, T.J., Kim, E.E., Tilbury, R., Bruner, J.M., Yung, W.K. Ann. Neurol. (1993) [Pubmed]
Abnormal cerebral glucose metabolism in long-term survivors of childhood acute lymphocytic leukemia. Phillips, P.C., Moeller, J.R., Sidtis, J.J., Dhawan, V., Steinherz, P.G., Strother, S.C., Ginos, J.Z., Rottenberg, D.A. Ann. Neurol. (1991) [Pubmed]
Contrasting metabolic impairment in frontotemporal degeneration and early onset Alzheimer's disease. Ibach, B., Poljansky, S., Marienhagen, J., Sommer, M., Männer, P., Hajak, G. Neuroimage (2004) [Pubmed]
Regional cerebral glucose metabolism in children with deterioration of one or more cognitive functions and continuous spike-and-wave discharges during sleep. Maquet, P., Hirsch, E., Metz-Lutz, M.N., Motte, J., Dive, D., Marescaux, C., Franck, G. Brain (1995) [Pubmed]
Cerebral glucose metabolism in women with panic disorder. Bisaga, A., Katz, J.L., Antonini, A., Wright, C.E., Margouleff, C., Gorman, J.M., Eidelberg, D. The American journal of psychiatry. (1998) [Pubmed]
Metabolic impairment in human amnesia: a PET study of memory networks. Fazio, F., Perani, D., Gilardi, M.C., Colombo, F., Cappa, S.F., Vallar, G., Bettinardi, V., Paulesu, E., Alberoni, M., Bressi, S. J. Cereb. Blood Flow Metab. (1992) [Pubmed]
Functional imaging of endocrine tumors: role of positron emission tomography. Pacak, K., Eisenhofer, G., Goldstein, D.S. Endocr. Rev. (2004) [Pubmed]
Insulin resistance in liver cirrhosis. Positron-emission tomography scan analysis of skeletal muscle glucose metabolism. Selberg, O., Burchert, W., vd Hoff, J., Meyer, G.J., Hundeshagen, H., Radoch, E., Balks, H.J., Müller, M.J. J. Clin. Invest. (1993) [Pubmed]
In vivo imaging of neuronal activation and plasticity in the rat brain by high resolution positron emission tomography (microPET). Kornblum, H.I., Araujo, D.M., Annala, A.J., Tatsukawa, K.J., Phelps, M.E., Cherry, S.R. Nat. Biotechnol. (2000) [Pubmed]
[18F]fluorodeoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability? Srinivasan, G., Kitsiou, A.N., Bacharach, S.L., Bartlett, M.L., Miller-Davis, C., Dilsizian, V. Circulation (1998) [Pubmed]
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. Downey, R.J., Akhurst, T., Ilson, D., Ginsberg, R., Bains, M.S., Gonen, M., Koong, H., Gollub, M., Minsky, B.D., Zakowski, M., Turnbull, A., Larson, S.M., Rusch, V. J. Clin. Oncol. (2003) [Pubmed]
Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. Chen, D.L., Ferkol, T.W., Mintun, M.A., Pittman, J.E., Rosenbluth, D.B., Schuster, D.P. Am. J. Respir. Crit. Care Med. (2006) [Pubmed]
Brain tumor imaging with PET and 2-[carbon-11]thymidine. Vander Borght, T., Pauwels, S., Lambotte, L., Labar, D., De Maeght, S., Stroobandt, G., Laterre, C. J. Nucl. Med. (1994) [Pubmed]
[18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Perani, D., Colombo, C., Bressi, S., Bonfanti, A., Grassi, F., Scarone, S., Bellodi, L., Smeraldi, E., Fazio, F. The British journal of psychiatry : the journal of mental science. (1995) [Pubmed]
Myocardial glucose uptake in patients with NIDDM and stable coronary artery disease. Mäki, M., Nuutila, P., Laine, H., Voipio-Pulkki, L.M., Haaparanta, M., Solin, O., Knuuti, J.M. Diabetes (1997) [Pubmed]
Images in neuroscience. Neuroimaging, I.PET with [18F]fluorodeoxyglucose. Tamminga, C.A. The American journal of psychiatry. (1995) [Pubmed]
Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Pietrini, P., Dani, A., Furey, M.L., Alexander, G.E., Freo, U., Grady, C.L., Mentis, M.J., Mangot, D., Simon, E.W., Horwitz, B., Haxby, J.V., Schapiro, M.B. The American journal of psychiatry. (1997) [Pubmed]
Errors introduced by tissue heterogeneity in estimation of local cerebral glucose utilization with current kinetic models of the [18F]fluorodeoxyglucose method. Schmidt, K., Lucignani, G., Moresco, R.M., Rizzo, G., Gilardi, M.C., Messa, C., Colombo, F., Fazio, F., Sokoloff, L. J. Cereb. Blood Flow Metab. (1992) [Pubmed]
A physiologic imaging pilot study of breast cancer treated with AZD2171. Miller, K.D., Miller, M., Mehrotra, S., Agarwal, B., Mock, B.H., Zheng, Q.H., Badve, S., Hutchins, G.D., Sledge, G.W. Clin. Cancer Res. (2006) [Pubmed]
Myocardial viability in patients with chronic coronary artery disease. Comparison of 99mTc-sestamibi with thallium reinjection and [18F]fluorodeoxyglucose. Dilsizian, V., Arrighi, J.A., Diodati, J.G., Quyyumi, A.A., Alavi, K., Bacharach, S.L., Marin-Neto, J.A., Katsiyiannis, P.T., Bonow, R.O. Circulation (1994) [Pubmed]
[18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Antoine, J.C., Cinotti, L., Tilikete, C., Bouhour, F., Camdessanché, J.P., Confavreux, C., Vighetto, A., Renault-Mannel, V., Michel, D., Honnorat, J. Ann. Neurol. (2000) [Pubmed]
Source propagation of interictal spikes in temporal lobe epilepsy. Correlations between spike dipole modelling and [18F]fluorodeoxyglucose PET data. Merlet, I., Garcia-Larrea, L., Grégoire, M.C., Lavenne, F., Mauguière, F. Brain (1996) [Pubmed]
Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Baer, F.M., Voth, E., Schneider, C.A., Theissen, P., Schicha, H., Sechtem, U. Circulation (1995) [Pubmed]
Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction. Implications for the pathophysiology of chronic myocardial hibernation. Gerber, B.L., Vanoverschelde, J.L., Bol, A., Michel, C., Labar, D., Wijns, W., Melin, J.A. Circulation (1996) [Pubmed]
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Breier, A., Malhotra, A.K., Pinals, D.A., Weisenfeld, N.I., Pickar, D. The American journal of psychiatry. (1997) [Pubmed]
Reproducibility of regional brain metabolic responses to lorazepam. Wang, G.J., Volkow, N.D., Overall, J., Hitzemann, R.J., Pappas, N., Pascani, K., Fowler, J.S. J. Nucl. Med. (1996) [Pubmed]
Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. Tjuvajev, J.G., Macapinlac, H.A., Daghighian, F., Scott, A.M., Ginos, J.Z., Finn, R.D., Kothari, P., Desai, R., Zhang, J., Beattie, B. J. Nucl. Med. (1994) [Pubmed]
[18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Mamede, M., Higashi, T., Kitaichi, M., Ishizu, K., Ishimori, T., Nakamoto, Y., Yanagihara, K., Li, M., Tanaka, F., Wada, H., Manabe, T., Saga, T. Neoplasia (2005) [Pubmed]
Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. Chung, J.K., Lee, Y.J., Kim, C., Choi, S.R., Kim, M., Lee, K., Jeong, J.M., Lee, D.S., Jang, J.J., Lee, M.C. J. Nucl. Med. (1999) [Pubmed]
Cerebral glucose metabolism in adolescent girls with attention-deficit/hyperactivity disorder. Ernst, M., Cohen, R.M., Liebenauer, L.L., Jons, P.H., Zametkin, A.J. Journal of the American Academy of Child and Adolescent Psychiatry. (1997) [Pubmed]
Glucose metabolism in the rat frontal cortex recovered without the recovery of choline acetyltransferase activity after lesioning of the nucleus basalis magnocellularis. Katsumi, Y., Hayashi, T., Oyanagi, C., Nagahama, Y., Yamauchi, H., Ono, S., Fukuyama, H., Shibasaki, H. Neurosci. Lett. (2000) [Pubmed]
Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J., Bormans, G., Thomas, J., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., Verhoef, G. Blood (2003) [Pubmed]
Positron emission tomography studies of cerebral glucose metabolism in chronic partial epilepsy. Abou-Khalil, B.W., Siegel, G.J., Sackellares, J.C., Gilman, S., Hichwa, R., Marshall, R. Ann. Neurol. (1987) [Pubmed]
Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Jagust, W., Gitcho, A., Sun, F., Kuczynski, B., Mungas, D., Haan, M. Ann. Neurol. (2006) [Pubmed]
PET and MRI of the thalamus in never-medicated patients with schizophrenia. Buchsbaum, M.S., Someya, T., Teng, C.Y., Abel, L., Chin, S., Najafi, A., Haier, R.J., Wu, J., Bunney, W.E. The American journal of psychiatry. (1996) [Pubmed]
Cerebral metabolic relationships for selected brain regions in Alzheimer's, Huntington's, and Parkinson's diseases. Metter, E.J., Riege, W.H., Kameyama, M., Kuhl, D.E., Phelps, M.E. J. Cereb. Blood Flow Metab. (1984) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.